Squarepoint’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-143,966
| Closed | -$2.9M | – | 4705 |
|
|
2026
Q1 | $2.9M | Buy |
+143,966
| New | +$2.32M | ﹤0.01% | 1914 |
|
|
2025
Q3 | – | Sell |
-26,386
| Closed | -$298K | – | 4675 |
|
|
2025
Q2 | $298K | Buy |
+26,386
| New | +$323K | ﹤0.01% | 3689 |
|
|
2024
Q4 | – | Sell |
-25,749
| Closed | -$298K | – | 5275 |
|
|
2024
Q3 | $298K | Buy |
+25,749
| New | +$324K | ﹤0.01% | 3449 |
|
|
2023
Q2 | – | Sell |
-14,432
| Closed | -$113K | – | 3793 |
|
|
2023
Q1 | $113K | Buy |
+14,432
| New | +$108K | ﹤0.01% | 2945 |
|
|
2021
Q3 | – | Sell |
-8,919
| Closed | -$214K | – | 3174 |
|
|
2021
Q2 | $214K | Sell |
8,919
-14,822
| -62% | -$388K | ﹤0.01% | 2778 |
|
|
2021
Q1 | $610K | Buy |
+23,741
| New | +$624K | ﹤0.01% | 1869 |
|
|
2020
Q3 | – | Sell |
-14,853
| Closed | -$180K | – | 2664 |
|
|
2020
Q2 | $180K | Sell |
14,853
-61,057
| -80% | -$649K | ﹤0.01% | 1852 |
|
|
2020
Q1 | $581K | Sell |
75,910
-47,133
| -38% | -$636K | 0.01% | 962 |
|
|
2019
Q4 | $2.19M | Sell |
123,043
-844
| -0.7% | -$11K | 0.01% | 854 |
|
|
2019
Q3 | $1.44M | Buy |
123,887
+52,643
| +74% | +$851K | 0.01% | 997 |
|
|
2019
Q2 | $1.58M | Buy |
+71,244
| New | +$1.67M | 0.02% | 984 |
|
Other funds holding KALV
Squarepoint's KALV Position: Q2 2026 in Review
Squarepoint sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 143,966 shares — an estimated $2.9M sold.
Squarepoint first reported a position in KALV in Q2 2019 and held it in 11 quarters. The position peaked at $2.9M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Squarepoint reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Squarepoint sold 143,966 KalVista Pharmaceuticals shares in Q2 2026, an estimated $2.9M.
- Squarepoint first reported a position in KalVista Pharmaceuticals in Q2 2019 and held it in 11 quarters.
- Squarepoint's KalVista Pharmaceuticals position peaked at $2.9M in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.